CLSD PE Ratio & Valuation,Is CLSD Overvalued

CLSD Relative Valuation

CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CLSD is overvalued; if below, it's undervalued.

Historical Valuation

Clearside Biomedical Inc (CLSD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 3.48 is considered Undervalued compared with the five-year average of -11.33. The fair price of Clearside Biomedical Inc (CLSD) is between 2.35 to 8.48 according to relative valuation methord. Compared to the current price of 0.35 USD , Clearside Biomedical Inc is Undervalued By 85.06%.

Relative Value

Fair Zone

2.35-8.48

Current Price：0.35

85.06%

Undervalued

-0.12

0.00

EV/EBITDA

Clearside Biomedical Inc. (CLSD) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.30. The thresholds are as follows: Strongly Undervalued below -1.83, Undervalued between -1.83 and -0.76, Fairly Valued between 1.37 and -0.76, Overvalued between 1.37 and 2.44, and Strongly Overvalued above 2.44. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.12

EV/EBIT

Clearside Biomedical Inc. (CLSD) has a current EV/EBIT of -2.12. The 5-year average EV/EBIT is -0.16. The thresholds are as follows: Strongly Undervalued below -54.53, Undervalued between -54.53 and -27.35, Fairly Valued between 27.02 and -27.35, Overvalued between 27.02 and 54.20, and Strongly Overvalued above 54.20. The current Forward EV/EBIT of -2.12 falls within the Historic Trend Line -Fairly Valued range.

3.48

Clearside Biomedical Inc. (CLSD) has a current PS of 3.48. The 5-year average PS is 110.55. The thresholds are as follows: Strongly Undervalued below -119.56, Undervalued between -119.56 and -4.50, Fairly Valued between 225.61 and -4.50, Overvalued between 225.61 and 340.67, and Strongly Overvalued above 340.67. The current Forward PS of 3.48 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Clearside Biomedical Inc. (CLSD) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.08. The thresholds are as follows: Strongly Undervalued below -23.54, Undervalued between -23.54 and -14.31, Fairly Valued between 4.14 and -14.31, Overvalued between 4.14 and 13.37, and Strongly Overvalued above 13.37. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Clearside Biomedical Inc. (CLSD) has a current P/FCF of 0.00. The 5-year average P/FCF is 26.47. The thresholds are as follows: Strongly Undervalued below -105.70, Undervalued between -105.70 and -39.62, Fairly Valued between 92.56 and -39.62, Overvalued between 92.56 and 158.65, and Strongly Overvalued above 158.65. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Clearside Biomedical Inc (CLSD) has a current Price-to-Book (P/B) ratio of -0.04. Compared to its 3-year average P/B ratio of -0.29 , the current P/B ratio is approximately -86.41% higher. Relative to its 5-year average P/B ratio of 3.81, the current P/B ratio is about -101.04% higher. Clearside Biomedical Inc (CLSD) has a Forward Free Cash Flow (FCF) yield of approximately -1013.36%. Compared to its 3-year average FCF yield of -39.63%, the current FCF yield is approximately 2456.96% lower. Relative to its 5-year average FCF yield of -25.73% , the current FCF yield is about 3838.16% lower.

-0.04

P/B

Median3y

-0.29

Median5y

3.81

-1013.36

FCF Yield

Median3y

-39.63

Median5y

-25.73

Competitors Valuation Multiple

The average P/S ratio for CLSD's competitors is 0.00, providing a benchmark for relative valuation. Clearside Biomedical Inc Corp (CLSD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -80.64%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CLSD decreased by 97.12% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -740.66 to -2.97K.

The secondary factor is the Revenue Growth, contributed -80.64%to the performance.

Overall, the performance of CLSD in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-80.64%

1.04M → 201.00K

Revenue Growth

301.15%

-740.66 → -2.97K

Margin Expansion

-317.63%

0.04 → -0.08

P/E Change

-97.12%

14.25 → 0.41

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Clearside Biomedical Inc (CLSD) currently overvalued or undervalued?

What is Clearside Biomedical Inc (CLSD) fair value?

CLSD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Clearside Biomedical Inc (CLSD) is between 2.35 to 8.48 according to relative valuation methord.

How does CLSD's valuation metrics compare to the industry average?

What is the current P/B ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

As of Dec 16 2025, Clearside Biomedical Inc (CLSD) has a P/B ratio of -0.04. This indicates that the market values CLSD at -0.04 times its book value.

What is the current FCF Yield for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

As of Dec 16 2025, Clearside Biomedical Inc (CLSD) has a FCF Yield of -1013.36%. This means that for every dollar of Clearside Biomedical Inc’s market capitalization, the company generates -1013.36 cents in free cash flow.

What is the current Forward P/E ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

As of Dec 16 2025, Clearside Biomedical Inc (CLSD) has a Forward P/E ratio of -0.12. This means the market is willing to pay $-0.12 for every dollar of Clearside Biomedical Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

As of Dec 16 2025, Clearside Biomedical Inc (CLSD) has a Forward P/S ratio of 3.48. This means the market is valuing CLSD at $3.48 for every dollar of expected revenue over the next 12 months.

CLSD Valuation

CLSD Valuation

CLSD Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is Clearside Biomedical Inc (CLSD) currently overvalued or undervalued?

What is Clearside Biomedical Inc (CLSD) fair value?

How does CLSD's valuation metrics compare to the industry average?

What is the current P/B ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

What is the current FCF Yield for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

What is the current Forward P/E ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?

What is the current Forward P/S ratio for Clearside Biomedical Inc (CLSD) as of Dec 16 2025?